Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies.
Head and neck cancer
immune checkpoint inhibitors
rare cancer
Journal
Exploration of targeted anti-tumor therapy
ISSN: 2692-3114
Titre abrégé: Explor Target Antitumor Ther
Pays: United States
ID NLM: 101770662
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
04
2021
accepted:
29
10
2021
entrez:
1
9
2022
pubmed:
1
1
2021
medline:
1
1
2021
Statut:
ppublish
Résumé
The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In recent years, the deeper and increasing knowledge on the genomic landscape and the upcoming new data on immunotherapy enacted by HNSCCs have led to successful therapeutic targeting of the immune system. Immune checkpoint inhibitors (ICIs) have changed state of the art in R/M patients and could have a potential role even in early disease. The purpose of this work is to summarize the role of immunotherapy for R/M HNSCC in clinical practice, with insights about future perspectives. Updated immunotherapy results in other R/M head and neck cancers such as thyroid, salivary glands, nasopharynx, sinonasal cancers, and nuclear protein in testis (NUT) are presented.
Identifiants
pubmed: 36046116
doi: 10.37349/etat.2021.00062
pii: etat-02-100262
pmc: PMC9400733
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
522-542Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Laura D. Locati reports grant and other financial relationships with Eisai, Ipsen, Merck Serono, MSD, BMS, Lilly. Lisa Licitra declares the following conflicts of interests: receipt of grants/research supports (Funds received by my institution for clinical studies and research activities in which I am involved) from AstraZeneca, BMS, Boehringer Ingelheim, Celgene International, Debiopharm International SA, Eisai, Exelixis Inc, Hoffmann-La Roche Ltd, IRX Therapeutics inc, Medpace Inc, Merck-Serono, MSD, Novartis, Pfizer, Roche; receipt of honoraria or consultation fees (for public speaking/teaching in medical meetings and/or for expert opinion in advisory boards) from AstraZeneca, Bayer, BMS, Eisai, MSD, Merck-Serono, Boehringer Ingelheim, Novartis, Roche, Debiopharm International SA, Sobi, Ipsen, Incyte Biosciences Italy SRL, Doxa Pharma, Amgen, Nanobiotics Sa, and GSK. The remaining authors declare no conflicts of interest.
Références
Am J Surg Pathol. 2008 Jun;32(6):828-34
pubmed: 18391746
Eur J Cancer. 2019 Jan;107:142-152
pubmed: 30576970
Int J Mol Sci. 2020 Jun 16;21(12):
pubmed: 32560253
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Expert Opin Investig Drugs. 2019 May;28(5):435-443
pubmed: 30897975
Cancer. 2020 Jan 1;126(9):1888-1894
pubmed: 32031693
J Clin Invest. 2019 Oct 1;129(10):4276-4289
pubmed: 31483290
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32641320
Head Neck. 2016 May;38(5):724-31
pubmed: 25522335
Lancet. 2019 Jul 6;394(10192):64-80
pubmed: 31178151
Oral Oncol. 2019 Jan;88:29-38
pubmed: 30616794
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Front Immunol. 2019 May 31;10:1206
pubmed: 31214178
Sci Rep. 2020 Oct 12;10(1):16988
pubmed: 33046752
N Engl J Med. 2009 Nov 5;361(19):1838-47
pubmed: 19890126
Clin Cancer Res. 2017 Dec 15;23(24):7569-7583
pubmed: 29025766
BioDrugs. 2018 Aug;32(4):311-317
pubmed: 29980987
Tumori. 2021 Jun;107(3):188-195
pubmed: 32924878
Ann Oncol. 2020 Jul;31(7):942-950
pubmed: 32294530
J Immunother Cancer. 2019 Apr 3;7(1):96
pubmed: 30944020
Ther Adv Med Oncol. 2020 Jul 20;12:1758835920915983
pubmed: 32733604
J Immunother Cancer. 2017 Jul 18;5(1):53
pubmed: 28716061
J Clin Oncol. 1992 Aug;10(8):1245-51
pubmed: 1634913
Nat Rev Endocrinol. 2020 Nov;16(11):629-641
pubmed: 32839578
Am J Surg Pathol. 2012 Aug;36(8):1222-7
pubmed: 22790861
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Nat Med. 2019 May;25(5):759-766
pubmed: 31036879
Lancet Oncol. 2018 Oct;19(10):1338-1350
pubmed: 30213452
J Clin Oncol. 2005 May 20;23(15):3562-7
pubmed: 15908667
J Clin Oncol. 2020 Aug 10;38(23):2620-2627
pubmed: 32364844
Oral Oncol. 2017 Feb;65:114-118
pubmed: 28341276
BMC Cancer. 2019 Mar 4;19(1):196
pubmed: 30832606
Ann Oncol. 2012 Feb;23(2):435-41
pubmed: 21586688
Lancet. 2016 Oct 15;388(10054):1883-1892
pubmed: 27567279
Cell. 2015 Feb 26;160(5):963-976
pubmed: 25723170
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Ann Oncol. 2020 Jul;31(7):830-831
pubmed: 32387452
Clin Cancer Res. 2020 Jun 15;26(12):2859-2870
pubmed: 32060100
Oral Oncol. 2019 Mar;90:94-101
pubmed: 30846184
Ann Oncol. 2017 Nov 01;28(11):2813-2819
pubmed: 29045520
Ann Oncol. 2019 Dec 1;30(12):1856-1883
pubmed: 31549998
Future Oncol. 2019 Mar;15(7):717-726
pubmed: 30638399
J Interferon Cytokine Res. 2018 Feb;38(2):45-68
pubmed: 29443657
JAMA Oncol. 2019 Jan 1;5(1):67-73
pubmed: 30267032
J Clin Oncol. 2018 May 10;36(14):1412-1418
pubmed: 29584545
Oncotarget. 2014 Dec 15;5(23):12189-202
pubmed: 25361008
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
J Clin Oncol. 2019 Jan 10;37(2):125-134
pubmed: 30452336
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
J Clin Oncol. 2019 Feb 20;37(6):504-512
pubmed: 30615549
J Clin Oncol. 2018 Jan 1;36(1):7-13
pubmed: 29072975
Lancet Oncol. 2021 Apr;22(4):463-475
pubmed: 33684370
JAMA Oncol. 2019 Feb 1;5(2):195-203
pubmed: 30383184
Curr Opin Oncol. 2020 May;32(3):203-209
pubmed: 32195680
Ann Oncol. 2017 Nov 01;28(11):2820-2826
pubmed: 28950305
Nat Rev Immunol. 2020 Mar;20(3):173-185
pubmed: 31676858
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
Cancer Res. 2013 Jan 1;73(1):128-38
pubmed: 23135914
BMC Cancer. 2018 Dec 17;18(1):1254
pubmed: 30558663
Ann Oncol. 2021 Apr;32(4):452-465
pubmed: 33358989
Cell Tissue Res. 2016 Sep;365(3):607-19
pubmed: 27474009
J Clin Oncol. 2018 Nov 10;36(32):3223-3230
pubmed: 30265610
J Clin Oncol. 2019 Jun 20;37(18):1529-1537
pubmed: 30939095
J Clin Oncol. 2005 Dec 10;23(35):8942-9
pubmed: 16204009
Laryngoscope. 2020 Apr;130(4):857-865
pubmed: 31369156
Cells. 2020 Sep 15;9(9):
pubmed: 32942747
Chin Clin Oncol. 2016 Apr;5(2):22
pubmed: 27121882
Am J Clin Oncol. 2018 Nov;41(11):1083-1088
pubmed: 29462123
Blood. 2005 Mar 1;105(5):1898-904
pubmed: 15542583
Front Immunol. 2018 Apr 23;9:830
pubmed: 29740440
Methods Mol Biol. 2015;1317:365-82
pubmed: 26072418
Lancet Oncol. 2021 Aug;22(8):1162-1174
pubmed: 34174189
Clin Exp Immunol. 2020 May;200(2):108-119
pubmed: 31828774